about
Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinomaPolo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.Nonampullary Duodenal Adenomas Rarely Recur after Complete Endoscopic Resection: A Swiss Experience Including a Literature Review.Safe and successful resection of difficult GI lesions using a novel single-step full-thickness resection device (FTRD(®)).Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.A hedgehog survival pathway in 'undead' lipotoxic hepatocytes.Targeting PDGFR-β in CholangiocarcinomaMyofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells.Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice.Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection.Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cellsElderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C.Targeting tumor stroma: exploiting apoptotic priming.Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.Stent-over-sponge (SOS): a novel technique complementing endosponge therapy for foregut leaks and perforations.Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease.Contrast-enhanced ultrasound of histologically proven liver hemangiomas.Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin DReceptor (NR 1I1) variants on fibrosis progression rate in HCV patientsUnusual cause of biliary colic in a Swiss farmer[Diagnosis and therapy of rheumatoid arthritis][The systolic heart sound][Answers to questions on rheumatoid arthritis from Practice No. 23]Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetil-associated colitis[Treatment of chronic hepatitis B and C - update 2010]Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinomaThe EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitisAutoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents
P50
Q34044638-36B866D5-9CAA-44EA-81FE-6A04771AACC8Q34251524-D36BA290-1174-4084-9954-A0079C1F3D3AQ36545163-4FA93659-300E-4D68-AE45-A36675F71124Q37262757-6A8D479D-66E3-4E93-9693-4119BA4C1015Q38602087-7F5A6FFE-AC4F-423A-956A-CB5C70D93C8CQ38701006-ABC7F898-FA22-4541-A112-3EB356AC97C9Q38812588-F8601253-17F4-4027-AFD9-0EE9E5809523Q38893743-810DBF9F-96AF-4C19-939F-64254BC79C3FQ39062578-3201DDF0-94AA-461D-9AEE-62AED2603B3DQ39131172-D40E063F-0F1A-4A35-87BF-D9432D0CF096Q39340993-AD85584B-782E-479B-81AE-2F9B3575B187Q39434606-2B44BB2F-D02E-4440-94CA-00845DFFE974Q39450591-D437ADB7-9C32-45EC-BD5A-D1B7B9DF9420Q39660064-3AC8D071-AA88-4FE5-B10F-5E2AE3CBCFE5Q40469011-99688C4D-7140-475C-B2E2-04DE70220A0FQ40617255-0732D424-6980-48E0-979B-EA966F672018Q40755053-0A7BAE5C-62C1-4FD9-8039-446FD2740A79Q42199556-3DE505C9-3207-4A64-945E-83B2A40971BFQ42269830-E68BEE57-2CB4-45B1-B277-95C0F45C8E73Q42999327-F598E489-7BB9-4CF2-AE76-96BDAB365801Q43127374-FEBEF5E2-FE27-42A1-B386-B186CD531D0BQ43162044-0A033923-C6AD-44B1-8C51-7521E423C7C0Q47205297-32C613C9-C90C-4201-B6FF-D85F9E875EC5Q47548409-E0806723-E804-4DC8-8895-179113959253Q47961293-89E46D90-FC3E-4174-B6A9-355DC2EEB6DFQ49547914-C968A6D2-1F30-448E-84C2-87835BAB7D0BQ53247066-6FADC4FA-A899-4BDD-B1EB-56DE6BC06C80Q53298107-CCF6965E-D6EF-4791-B6FA-DB04F940797AQ53484750-2BA47516-25B0-4FC7-9F95-02CBA4EBFAC7Q55360419-FCF3D4B6-4E80-4C65-8836-0583880746DCQ61218108-DA9214A2-0D40-4B69-95B1-BFF7315FCCB4Q82205649-6E4B8855-EC48-4BCC-9406-5A9F922AA349Q82641582-FE0B7032-D54D-4AA8-A16C-DA829620BD3CQ82798392-5878A5BA-4BDA-4472-825B-B7264DF4BCFFQ82798474-902BC93B-0289-4DB8-BDB7-ABCFF52ED8E4Q84202530-F24F429A-C7A5-4E17-A9B7-2612116AF63EQ84801503-6FAC7993-8E6F-4479-9E4D-841561CFFDE0Q90557164-2AB5B483-D8D1-4E6B-BE9E-3F074BC2B1EDQ91451009-4376B190-2E0C-4359-AA29-95697D9F13B0Q91705792-896DCFB4-DA3C-4D8C-A8A4-B679269C8341
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joachim C Mertens
@nl
Joachim C Mertens
@sl
Joachim C. Mertens
@en
Joachim C. Mertens
@es
type
label
Joachim C Mertens
@nl
Joachim C Mertens
@sl
Joachim C. Mertens
@en
Joachim C. Mertens
@es
prefLabel
Joachim C Mertens
@nl
Joachim C Mertens
@sl
Joachim C. Mertens
@en
Joachim C. Mertens
@es
P106
P108
P1153
26431048800
P21
P31
P496
0000-0003-2007-0308